InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of…
Biotechnology
DE, Jena [HQ]
Balance Sheet
8 Sheets · Starting from 2022In Million EUR. Margins, Growth Rates In %
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | 3.00 | 29.00 | 124.00 | 159.00 | 121.00 | 88.00 | 125.00 | 102.00 | |
|
Current
|
3.00 | 29.00 | 123.00 | 158.00 | 118.00 | 86.00 | 95.00 | 97.00 | |
| Cash And Equivalents | 3.00 | 29.00 | 123.00 | 55.00 | 33.00 | 25.00 | 26.00 | 16.00 | |
| Assets | 3.00 | 29.00 | 124.00 | 159.00 | 121.00 | 88.00 | 125.00 | 102.00 | |
| Accounts Receivables (AR) | - - | - - | - - | - - | - - | - - | - - | - - | |
| Inventory | - - | - - | - - | - - | - - | - - | - - | - - | |
| Short Term Investments | - - | - - | - - | 101.00 | 82.00 | 55.00 | 57.00 | 65.00 | |
| Other Current Assets | - - | - - | - - | - - | 1.00 | 3.00 | 10.00 | 14.00 | |
|
Non Current
|
- - | - - | - - | 1.00 | 2.00 | 1.00 | 29.00 | 4.00 | |
| Property, Plant, Equipment (Net) | - - | - - | - - | - - | 1.00 | - - | 1.00 | 1.00 | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | - - | - - | - - | |
| Goodwill | - - | - - | - - | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | - - | - - | - - | - - | - - | 27.00 | 2.00 | |
| Other Non Current Assets | - - | - - | - - | - - | - - | - - | - - | - - | |
| Liabilities | 21.00 | 55.00 | 4.00 | 7.00 | 14.00 | 10.00 | 19.00 | 14.00 | |
|
Current
|
- - | 1.00 | 4.00 | 7.00 | 14.00 | 10.00 | 18.00 | 13.00 | |
| Accounts Payable | - - | - - | 3.00 | 2.00 | 5.00 | -3.00 | - - | -3.00 | |
| Short Term Debt | - - | - - | - - | - - | - - | - - | - - | - - | |
| Deferred Revenue | - - | - - | - - | - - | - - | 1.00 | 1.00 | 6.00 | |
| Tax Payable | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | - - | - - | - - | 1.00 | 1.00 | - - | 8.00 | 1.00 | |
|
Non Current
|
20.00 | 53.00 | - - | - - | - - | - - | 1.00 | 1.00 | |
| Long Term Debt | - - | - - | - - | - - | - - | - - | 1.00 | - - | |
| Leasing Obligations | - - | - - | - - | - - | - - | - - | 1.00 | 1.00 | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Non Current Liabilities | 20.00 | 53.00 | - - | - - | - - | - - | - - | - - | |
| Equity | -17.00 | -25.00 | 119.00 | 151.00 | 107.00 | 77.00 | 105.00 | 88.00 | |
| Stockholders' Equity | -17.00 | -25.00 | 119.00 | 151.00 | 107.00 | 77.00 | 105.00 | 88.00 | |
| Retained Earnings | -18.00 | -27.00 | -51.00 | -81.00 | -134.00 | -168.00 | -213.00 | -243.00 | |
| Common Stock | - - | - - | 2.00 | 3.00 | 3.00 | 3.00 | 5.00 | 5.00 | |
| Preferred Stock | - - | - - | - - | - - | - - | - - | - - | - - | |
| Profit | -4.00 | -8.00 | -24.00 | -29.00 | -49.00 | -34.00 | -45.00 | -27.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | - - | - - | 170.00 | 211.00 | 213.00 | 216.00 | 283.00 | 289.00 | |
| Loss Other Compr. Income | - - | 1.00 | 167.00 | 18.00 | 25.00 | 26.00 | 30.00 | 36.00 |